Microspheres for controlled- or sustained-release delivery of therapeutics

{
  "publication_number": "US9381159B2",
  "country": "US",
  "kind": "B2",
  "title": "Microspheres for controlled- or sustained-release delivery of therapeutics",
  "abstract": "A new microsphere formulation (composition) for controlled- or sustained-release delivery of therapeutic ingredient(s), mainly peptides and proteins not over 10K in molecular weight, comprises at least a therapeutic ingredient, a helping agent (such as PH sensitive agent whose solubility is a function of pH) and a biodegradable polymer. The therapeutic ingredient(s) and the helping agent are in the form of fine particles, less than 1O um in diameter, encapsulated in the polymer which forms the microsphere matrix. A method for preparing the composition comprises a step of in-situ precipitating the therapeutic ingredient(s) and the helping agent to the fine particles and successive steps for forming the microspheres. Such a microsphere formulation offers a well-controlled release profile for prolonged period and encapsulation efficiency over 95%.",
  "claims": [
    "1. A composition comprising a plurality of microspheres, each microsphere comprising: a) a biodegradable polymer forming a matrix of the microsphere; b) a particulate GLP-1 receptor agonist distributed in the matrix of the microsphere; and c) a particulate helping agent selected from Mg(OH) 2, MgCO 3, and Zn(OH) 2 distributed in the matrix of the microsphere, wherein the particulate helping agent is less than 8.82 w/w % of the total mass of the microsphere wherein the particulate GLP-1 receptor agonist and the particulate helping agent are less than 10 μm in size and are encapsulated by the biodegradable polymer; and wherein the GLP-1 receptor agonist is exenatide.",
    "2. The composition of claim 1, wherein the biodegradable polymer is polylactic-co-glycolic acid (PLGA), polylactic acid (PLA), or polycaprolactone (PCL).",
    "3. The composition of claim 1 wherein the particulate GLP-1 receptor agonist and the particulate helping agent of Mg(OH) 2, MgCO 3, or Zn(OH) 2 are around 1 μm in size.",
    "4. A method to prepare the composition of claim 1, comprising, a) suspending the particulate GLP-1 receptor agonist and particulate Mg(OH) 2, MgCO 3, or Zn(OH) 2 in an organic solution having the biodegradable polymer and an organic solvent; b) dispersing the suspension made in step a) into an aqueous continuous phase to form embryonic microspheres; c) removing the organic solvent of the embryonic microspheres made in step b) to solidify them.",
    "5. The method of claim 4, wherein the particulate GLP-1 receptor agonist and the particulate Mg(OH) 2, MgCO 3, or Zn(OH) 2 are around 1 μm in size.",
    "6. The method of claim 4, in case the particulate GLP-1 receptor agonist or the particulate Mg(OH) 2, MgCO 3, or Zn(OH) 2 helping agent are over 10 μm in size, the method further comprising in situ precipitation to reduce the particle sizes by: a) dissolving the particulate GLP-1 receptor agonist in a polar solvent, b) dissolving Mg(OH) 2, MgCO 3, or Zn(OH) 2 in a small amount water; and c) mixing the solutions of steps a) or b) into the organic solution of the biodegradable polymer to precipitate the therapeutic ingredient or Mg(OH) 2, MgCO 3, or Zn(OH) 2 to particles less than 10 μm in size.",
    "7. The method of claim 6, wherein the solutions made in steps a) or b) are mixed into the organic solution of the biodegradable polymer at step c) to precipitate the particulate GLP-1 receptor agonist or Mg(OH) 2, MgCO 3, or Zn(OH) 2 to particles not over 1 μm in size.",
    "8. The method of claim 6, wherein the polar solvent is selected from DMSO and DMF.",
    "9. The method of claim 6, wherein the organic solvent in the organic solution of the biodegradable polymer is selected from dichloromethane and ethyl acetate.",
    "10. The method of claim 4, wherein the biodegradable polymer is selected from polylactic acid (PLA), polylactic-co-glycolic acid (PLGA), or polycaprolactone (PCL).",
    "11. The method of claim 4, wherein the aqueous continuous phase further includes polyvinyl alcohol as a surfactant.",
    "12. The composition of claim 1, wherein the content of the helping agent is less than 6.06 w/w % in the total mass of the microspheres."
  ],
  "description_excerpt": "This invention relates a composition of sustained release dosage form of exenatide, a peptide, and a method to formulate this dosage form.\n\nThe technical challenges for a polymer-based sustained-release dosage form of peptide or other water soluble ingredients comprise initial burst release, incomplete release, delayed release in the initial or any other dosing period, and degradation of the active ingredients due to acidity or generated from the polymer degradation. To ensure that the sustained-release dosage form injectable, the drug carrying polymers are often formulated to microsphere form, tens of microns in diameter, by which the active ingredients are microencapsulated. In this case, encapsulation efficiency and size control of the microspheres become a critical for therapeutically practical dosage forms. While several peptide-loaded microsphere formulations are available on the market, the above-mentioned issues have not yet been well addressed. This situation is especially true for exenatide microsphere formulation currently sold in the market, which released exenatide for a period of a week since the third week after administration. The present invention teaches microsphere composition and its formulation method for which the problems associated with microsphere formulation, especially for peptides and exenatide will be resolved.\n\nMicrospheres are formulated with a variety of reported methods, such as the solvent evaporation, coacervation, spray drying, spray freeze-drying, ultrason-assisted atomization, and microfluidization.",
  "cpc": [
    "A61K 9/1647",
    "A61K 38/22",
    "A61K 38/23",
    "A61K 38/25",
    "A61K 38/26",
    "A61K 38/31",
    "A61K 9/1611",
    "A61K 9/1694",
    "A61P 3/10"
  ],
  "ipc": [
    "A61K 38/22",
    "A61K 38/23",
    "A61K 38/25",
    "A61K 38/26",
    "A61K 38/31",
    "A61K 9/16",
    "A61K 38/16",
    "A61K 9/50",
    "A61P 3/10"
  ],
  "inventors": [
    "Tuo Jin",
    "Zhenhua Hu",
    "Weien Yuan"
  ],
  "filing_date": "2012-12-05",
  "publication_date": "2016-07-05",
  "grant_date": "2016-07-05",
  "priority_date": "2011-12-05",
  "application_number": "US-201214362575-A",
  "family_id": "46180527",
  "cited_by_count": 3,
  "citations": [
    "JPS57118512A",
    "US5912015A",
    "JP2002505671A",
    "US20020045582A1",
    "US6270700B1",
    "WO2002100343A3",
    "WO2002100343A2",
    "CN1732903A",
    "US20090004283A1",
    "JP2011506077A",
    "WO2010113177A2",
    "CN101658496A",
    "CN102488619A"
  ]
}